Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings per share (EPS) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -705.20.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 4 comparable quarters.
EARNINGS PER SHARE (EPS)
N/A
EARNINGS PER SHARE (EPS) AVG TTM
-2880.36
EARNINGS PER SHARE (EPS) AVG 3Y
-1920.24
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
BridgeBio Oncology Therapeutics Inc.
Market Cap
$296.20M
Earnings Per Share (EPS)
N/A
TTM Avg
-2880.36
3Y Avg
-1920.24
5Y Avg
N/A
Market Cap
$296.59M
Earnings Per Share (EPS)
-1.99
TTM Avg
-1.79
3Y Avg
-1.44
5Y Avg
-2.04
Market Cap
$291.84M
Earnings Per Share (EPS)
-0.23
TTM Avg
-0.20
3Y Avg
-1.19
5Y Avg
-1.02
Market Cap
$305.66M
Earnings Per Share (EPS)
-0.98
TTM Avg
-1.02
3Y Avg
-4.71
5Y Avg
-10.90
Market Cap
$288.68M
Earnings Per Share (EPS)
-1.11
TTM Avg
-0.10
3Y Avg
-2.07
5Y Avg
-8.75
Market Cap
$287.63M
Earnings Per Share (EPS)
-6.97
TTM Avg
-33.27
3Y Avg
-41.62
5Y Avg
-70.95
Market Cap
$308.22M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.02
3Y Avg
-0.02
5Y Avg
-0.02
Market Cap
$283.85M
Earnings Per Share (EPS)
-1.21
TTM Avg
-0.67
3Y Avg
-1.32
5Y Avg
-1.70
Market Cap
$279.83M
Earnings Per Share (EPS)
-1.05
TTM Avg
-1.40
3Y Avg
-1.83
5Y Avg
-1.95
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $296.20M | N/A | -2880.36 | -1920.24 | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $296.59M | -1.99 | -1.79 | -1.44 | -2.04 |
| Standard BioTools Inc. (LAB)vs › | $291.84M | -0.23 | -0.20 | -1.19 | -1.02 |
| Benitec Biopharma Inc. (BNTC)vs › | $305.66M | -0.98 | -1.02 | -4.71 | -10.90 |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.68M | -1.11 | -0.10 | -2.07 | -8.75 |
| Indaptus Therapeutics, Inc. (INDP)vs › | $287.63M | -6.97 | -33.27 | -41.62 | -70.95 |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $308.22M | N/A | -0.02 | -0.02 | -0.02 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.85M | -1.21 | -0.67 | -1.32 | -1.70 |
| Fate Therapeutics, Inc. (FATE)vs › | $279.83M | -1.05 | -1.40 | -1.83 | -1.95 |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | -1.39 | -0.76 | -0.82 | -19.50 |
Trailing EPS (TTM)
N/A
Forward EPS (Est.)
$-2.59
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -4.30 |
| 2024-12-31 | -5756.41 |
| 2022-12-31 | 0.00 |
| 2021-12-31 | 0.00 |
